Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phas...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2018-10-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | https://jkcvhl.com/index.php/jkcvhl/article/view/109 |
| Summary: | Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.
|
|---|---|
| ISSN: | 2203-5826 |